Medical imager Point Biomedical recaps with $25M

point-biomedical-logo.gifPoint Biomedical, a San Carlos, Calif., developer of new biomedical-imaging products, raised $25 million in a recapitalization, peHub reports. Such recapitalizations often amount to a kind of “reset button” for existing investors and lenders, and usually suggest that a startup has run into some kind of significant — but not insurmountable — obstacle.

Investors in the recap round include new investor Vedanta Opportunities Fund and existing investors William Blair Capital Partners, De Novo Ventures, Institutional Venture Partners, Saints Capital, Sprout Group and CHL Medical Partners. The recapitalization includes an additional $32.3 million that will become available to Point Bio once it attains an unspecified milestone, which it expects to occur in April.

There’s presumably a release about this, but Point Bio’s Web site has been down all morning, so for now I’m relying on peHub and VentureWire reports. I’ll update if the release turns up. According to VentureWire, Point Bio had previously raised over $110 million from a variety of venture-capital and private-equity firms.

Point Bio is developing a medical imaging and drug-delivery technology based on tiny, nested spheres it calls the BiSphere. This technology is currently in late-stage trials as an “imaging agent” that should make it possible to observe the flow of blood through the heart using ultrasound instead of more invasive methods. We previously covered the company when it raised money last July and described its technology in more detail there.

Next Story: Medical imager Point Biomedical recaps with $25M
Previous Story: Roundup: EBay’s Whitman to retire, Facebook-Nokia, Yahoo’s layoffs, more

Bookmark and Share

Tags: , , , , , , , , , , ,

Photo of David P. Hamilton

About the Author, David P. Hamilton

David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.

  • sparky
    Am not sure 100% but I think they having some layoffs. Been seeing people leaving. Fewer and fewer workers arrive everyday.

    Stage 2 must not of gone well.

    Story here for D.H.?